STOCK TITAN

Satellos Bioscience (MSLE) Financials

MSLE NASDAQ
FY2025 annual
Net Income -$24.9M n/m YoY
EPS (Diluted) -$1.70 YoY not available
Free Cash Flow -$23.6M n/m YoY
Operating Cash Flow -$23.6M n/m YoY
Market Cap $137.3M as of Nov 16, 2026
Price / Sales n/m no revenue reported
Price / Earnings n/m net loss, so no earnings multiple, FY2025
Price / Book 4.9x on $27.8M equity, Q4 FY2025

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 16, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (40-F/6-K) Latest period FY2025, ended Dec 31, 2025 Reported Currency USD FYE December

Newest figures come from the 40-F for FY2025, filed Mar 27, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the MSLE SEC filings page.

This page shows Satellos Bioscience Inc. (MSLE) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 2 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (40-F and 6-K reports).

Financial Health Signals

Financial health score not available

We do not publish a peer-relative financial health score for Satellos Bioscience Inc., because the score only covers companies whose filings and listing give us what it needs to compare them with their peers. The signals and metrics below are current.

Piotroski F-Score Partial
1/5

Satellos Bioscience Inc. passes 1 of 5 computable financial strength tests (4 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).

Earnings Quality No Cash Backing
N/A

Satellos Bioscience Inc. reported a net loss of $24.9M while operations used $23.6M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

Net Income
-$24.9M
YoYn/m

Satellos Bioscience Inc. reported a net loss of $24.9M in fiscal year 2025. The change from the prior year is not meaningful, because that figure was zero or negative.

EPS (Diluted)
-$1.70

Satellos Bioscience Inc. earned -$1.70 per diluted share (EPS) in fiscal year 2025.

Revenue

Not reported for fiscal year 2025.

EBITDA

Not reported for fiscal year 2025.

Cash & Balance Sheet

Free Cash Flow
-$23.6M
YoYn/m

Satellos Bioscience Inc. recorded an outflow of $23.6M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. The change from the prior year is not meaningful, because that figure was zero or negative.

Cash & Debt
$9.8M
YoY-75.5%

Satellos Bioscience Inc. held $9.8M in cash as of fiscal year 2025; no long-term debt figure is on record for that period.

Shares Outstanding
15M

Satellos Bioscience Inc. had 15M shares outstanding in fiscal year 2025.

Dividends Per Share

Not reported for fiscal year 2025.

Margins & Returns

Return on Equity
-89.5%
YoY-45.8pp

Satellos Bioscience Inc.'s ROE was -89.5% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 45.8 percentage points from the prior year.

Gross Margin

Not reported for fiscal year 2025.

Operating Margin

Not reported for fiscal year 2025.

Net Margin

Not reported for fiscal year 2025.

Capital Allocation

R&D Spending
$18.4M
YoY+28.3%

Satellos Bioscience Inc. invested $18.4M in research and development in fiscal year 2025. This represents an increase of 28.3% from the prior year.

Capital Expenditures
$6K
YoY+50.0%

Satellos Bioscience Inc. invested $6K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 50.0% from the prior year.

Share Buybacks

Not reported for fiscal year 2025.

MSLE Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

MSLE annual income statement
MetricFY2540-FFY2440-F
R&D Expenses$18.4M+28.3%$14.4M
Operating Income-$26.5Mn/m-$20.4M
Income Tax$172KN/A
Net Income-$24.9Mn/m-$20.6M
EPS (Basic)-$1.70-$2.16
EPS (Diluted)-$1.70-$2.16
Diluted Shares (Avg)15M10M

Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, SG&A Expenses, EBITDA, Interest Expense.

MSLE Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

MSLE annual balance sheet
MetricFY2540-FFY2440-F
Total Assets$31.9M-37.2%$50.7M
Current Assets$31.9M-37.2%$50.7M
Cash & Equivalents$9.8M-75.5%$40.1M
Total Liabilities$4.1M+14.6%$3.6M
Current Liabilities$4.1M+14.6%$3.6M
Non-Current Liabilities$0n/m$0
Total Equity$27.8M-41.1%$47.2M
Retained Earnings-$82.0Mn/m-$57.1M

Not reported in any period shown, so not listed: Short-Term Investments, Inventory, Accounts Receivable, Long-Term Investments, Goodwill, Long-Term Debt.

MSLE Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

MSLE annual cash flow statement
MetricFY2540-FFY2440-F
Operating Cash Flow-$23.6Mn/m-$18.3M
Capital Expenditures$6K+50.0%$4K
Free Cash Flow-$23.6Mn/m-$18.3M
Investing Cash Flow-$9.4M-302.3%$4.7M
Financing Cash Flow$2.2M-94.0%$37.6M

Not reported in any period shown, so not listed: Depreciation & Amortization, Stock-Based Compensation, Dividends Paid, Share Buybacks.

MSLE Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

MSLE annual financial ratios
MetricFY2540-FFY2440-F
Return on Equity-89.5%-45.8pp-43.8%
Return on Assets-78.0%-37.3pp-40.7%
Current Ratio7.77-6.4x14.16
Liabilities-to-Equity0.15+0.1x0.08

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Debt-to-Equity, Asset Turnover, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.

Company Fiscal year Revenue Net income Net margin Market cap Health score
Satellos Bioscience Inc. MSLE FY2025 N/A -$24.9M N/A $137.3M —
Armata Pharmaceuticals, Inc. ARMP FY2025 N/A -$173.8M N/A $111.2M —
Compass Therapeutics, Inc. CMPX FY2025 $0 -$66.5M N/A $119.1M —
Sionna Therapeutics, Inc. SION FY2025 N/A -$75.3M N/A $141.1M —
ALX Oncology Holdings Inc. ALXO FY2025 N/A -$101.7M N/A $138.3M —
NeOnc Technologies Holdings, Inc. NTHI FY2025 $40K N/A N/A $131.0M —

Frequently Asked Questions

No, Satellos Bioscience Inc. (MSLE) reported a net loss of $24.9M in fiscal year 2025.

Satellos Bioscience Inc. (MSLE) reported diluted earnings per share of -$1.70 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Satellos Bioscience Inc. (MSLE) has a return on equity of -89.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

Satellos Bioscience Inc. (MSLE) recorded an outflow of $23.6M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

Satellos Bioscience Inc. (MSLE) recorded an outflow of $23.6M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

Satellos Bioscience Inc. (MSLE) had $31.9M in total assets as of fiscal year 2025, including both current and long-term assets.

Satellos Bioscience Inc. (MSLE) invested $6K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

Satellos Bioscience Inc. (MSLE) invested $18.4M in research and development during fiscal year 2025.

Satellos Bioscience Inc. (MSLE) had 15M shares outstanding as of fiscal year 2025.

Satellos Bioscience Inc. (MSLE) had a current ratio of 7.77 as of fiscal year 2025, which is generally considered healthy.

Satellos Bioscience Inc. (MSLE) had a liabilities-to-equity ratio of 0.15 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.

Satellos Bioscience Inc. (MSLE) had a return on assets of -78.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Satellos Bioscience Inc. (MSLE) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $137.3M as of Nov 16, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Satellos Bioscience Inc. (MSLE) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $137.3M as of Nov 16, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Satellos Bioscience Inc. (MSLE) has a Piotroski F-Score of 1 out of 5 computable signals; 4 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Satellos Bioscience Inc. (MSLE) reported a net loss of $24.9M while operations used $23.6M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Back to top